Drug Trial Radar · NCT07611357
[18F]F-AraG PET Imaging in Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
May 16, 2026
Primary completion
Sep 16, 2029
Study completion Dec 16, 2029
Sponsor
- Lead sponsor
- CellSight Technologies, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- University of California, Davis
- First posted
- May 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the use of \[18F\]F-AraG PET/CT imaging to quantify activated T cell involvement in patients with Alzheimer's disease (AD). Participants will undergo total-body dynamic PET imaging to assess tracer uptake in the brain and peripheral organs. Results will be compared between participants with AD and healthy controls to characterize both central nervous system and systemic immune alterations in AD
Conditions
- Alzheimer Disease (AD)
Interventions
Drug: [18F]F-AraG (PET tracer)Drug
Dose: \~5 mCi IV bolus. Procedure: Total-body PET/CT dynamic imaging. Blood samples will be collected during scan.
Primary outcomes
What the sponsor says the trial is designed to measure.
- [¹⁸F]F-AraG uptake in the brain of patients with ADTime frame: Imaging visit (~70 minutes)
- [¹⁸F]F-AraG uptake kinetics in the brain of patients with ADTime frame: Imaging visit (~70 minutes)
- [¹⁸F]F-AraG vascular kinetics in the brain of patients with ADTime frame: Imaging visit (~70 minutes)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.